June 20 2013 | By Márcio Barra
Tecfidera, Biogen’s idec of first-line oral treatment for people with relapsing forms of Multiple Sclerosis approved back in March in the US and EU, is having a very impressive start, selling so well that it’s expected to break the blockbuster barrier by next year according to the The Wall Street Journal. But the demand is such among patients, doctors and pharmacies that supply hasn’t been able to fully satisfy the demand. Supply chain and manufacturing snags also interfered with distribution, said Biogen’s CEO George Scangos.
View original post 252 more words